Correlation between troglitazone cytotoxicity and drug metabolic enzyme activities in cryopreserved human hepatocytes.

Troglitazone (TRO) was developed for the treatment of type II diabetes. It was withdrawn from use due to idiosyncratic liver damage and failure. The mechanism of toxicity is still not determined, moreover, it is still not clear whether toxicity is due to the parent compound or its metabolite(s).